Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (...
Saved in:
: | |
---|---|
Year of Publication: | 2019 |
Language: | English |
Physical Description: | 1 electronic resource (204 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993548383104498 |
---|---|
ctrlnum |
(CKB)4100000010106166 (oapen)https://directory.doabooks.org/handle/20.500.12854/61518 (EXLCZ)994100000010106166 |
collection |
bib_alma |
record_format |
marc |
spelling |
Contel, Maria auth Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile MDPI - Multidisciplinary Digital Publishing Institute 2019 1 electronic resource (204 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile. English ?-? stacking encapsulation oxindolimine-metal complexes cyclodextrin platinum iodido complexes distribution coefficient antiproliferative activity anticancer agents nanotubes ruthenium platinum Log kw nanoparticles drug discovery metal complex metallodrugs isatin-derived ligands anticancer drug upconverting nanoparticles pyridine benzimidazole dendrimers liposomes thiophene angiogenesis micelles HSA oxidation platinum(IV) imaging chromatographic lipophilicity parameter amidophosphine copper and iron chelators in cancer Log P biomacromolecules bones DNA cleavage stopped-flow spectroscopy silver phosphonates transmetalation metallomics MRI fluorescence quenching partition coefficient gold fingers anticancer HSA binding gold ?0 targeting metastasis DNA interaction antimigration cytotoxicity HPLC ruthenium complexes zinc finger proteins Gold(III) complexes aquaporins antiproliferative protein-DNA recognition photoactivation lipophilicity cancer 1-methylcytosine PET 3-03921-315-6 |
language |
English |
format |
eBook |
author |
Contel, Maria |
spellingShingle |
Contel, Maria Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
author_facet |
Contel, Maria |
author_variant |
m c mc |
author_sort |
Contel, Maria |
title |
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
title_full |
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
title_fullStr |
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
title_full_unstemmed |
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
title_auth |
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
title_new |
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
title_sort |
unconventional anticancer metallodrugs and strategies to improve their pharmacological profile |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2019 |
physical |
1 electronic resource (204 p.) |
isbn |
3-03921-316-4 3-03921-315-6 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT contelmaria unconventionalanticancermetallodrugsandstrategiestoimprovetheirpharmacologicalprofile |
status_str |
n |
ids_txt_mv |
(CKB)4100000010106166 (oapen)https://directory.doabooks.org/handle/20.500.12854/61518 (EXLCZ)994100000010106166 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile |
_version_ |
1796649014575235074 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04362nam-a2201045z--4500</leader><controlfield tag="001">993548383104498</controlfield><controlfield tag="005">20231214133616.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2019 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03921-316-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000010106166</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/61518</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000010106166</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Contel, Maria</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (204 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">?-? stacking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">encapsulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxindolimine-metal complexes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cyclodextrin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">platinum iodido complexes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">distribution coefficient</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antiproliferative activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticancer agents</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanotubes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ruthenium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">platinum</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Log kw</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug discovery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metal complex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metallodrugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">isatin-derived ligands</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticancer drug</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">upconverting nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pyridine benzimidazole</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dendrimers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liposomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">thiophene</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">micelles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HSA oxidation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">platinum(IV)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chromatographic lipophilicity parameter</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">amidophosphine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">copper and iron chelators in cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Log P</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomacromolecules</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bones</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA cleavage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stopped-flow spectroscopy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">silver</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phosphonates</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transmetalation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metallomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MRI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fluorescence quenching</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">partition coefficient</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gold fingers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HSA binding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gold</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">?0</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimigration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HPLC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ruthenium complexes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">zinc finger proteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Gold(III) complexes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aquaporins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antiproliferative</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protein-DNA recognition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">photoactivation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipophilicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">1-methylcytosine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PET</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03921-315-6</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-02-27 23:13:02 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-02-01 22:26:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338777490004498&Force_direct=true</subfield><subfield code="Z">5338777490004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338777490004498</subfield></datafield></record></collection> |